Inspection Record

Mantra Pharma Inc. — Health Canada Inspection Findings

Health CanadaInspected 2021-12-07 6 findingsTraining and personnelOther quality systemStability and storageEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

The job descriptions for personnel, the authority given to personnel, and/or the delegation of duties was inadequate and/or undocumented.

2Other quality system

The implementation of a self-inspection program was inadequate.

3Stability and storage

The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.

4Equipment and facility

The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.

5Other quality system

The master production documents were inadequate.

6Stability and storage

The ongoing stability program for a drug was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2021-12-07. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Mantra Pharma Inc. company profile — full history Health Canada documents, 2021 Go to Findings search